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A B S T R A C T   
Histidine-containing dipeptides (HCDs) are abundantly expressed in striated muscles. Although important prop-
erties have been ascribed to HCDs, including H+ buffering, regulation of Ca2+ transients and protection against 
oxidative stress, it remains unknown whether they play relevant functions in vivo. To investigate the in vivo roles of 
HCDs, we developed the first carnosine synthase knockout (CARNS1− /− ) rat strain to investigate the impact of an 
absence of HCDs on skeletal and cardiac muscle function. Male wild-type (WT) and knockout rats (4 months-old) 
were used. Skeletal muscle function was assessed by an exercise tolerance test, contractile function in situ and 
muscle buffering capacity in vitro. Cardiac function was assessed in vivo by echocardiography and cardiac electrical 
activity by electrocardiography. Cardiomyocyte contractile function was assessed in isolated cardiomyocytes by 
measuring sarcomere contractility, along with the determination of Ca2+ transient. Markers of oxidative stress, 
mitochondrial function and expression of proteins were also evaluated in cardiac muscle. Animals were supple-
mented with carnosine (1.8% in drinking water for 12 weeks) in an attempt to rescue tissue HCDs levels and 
function. CARNS1− /− resulted in the complete absence of carnosine and anserine, but it did not affect exercise 
capacity, skeletal muscle force production, fatigability or buffering capacity in vitro, indicating that these are not 
essential for pH regulation and function in skeletal muscle. In cardiac muscle, however, CARNS1− /− resulted in a 
significant impairment of contractile function, which was confirmed both in vivo and ex vivo in isolated sarcomeres. 
Impaired systolic and diastolic dysfunction were accompanied by reduced intracellular Ca2+ peaks and slowed 
Ca2+ removal, but not by increased markers of oxidative stress or impaired mitochondrial respiration. No relevant 
increases in muscle carnosine content were observed after carnosine supplementation. Results show that a primary 
function of HCDs in cardiac muscle is the regulation of Ca2+ handling and excitation-contraction coupling.  
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1. Introduction 
Histidine-containing dipeptides (HCDs) are abundantly found in 
skeletal and cardiac muscles, kidneys and brains of humans and other 
mammals [1]. Carnosine (β-alanyl-L-histidine) and its methylated 
analogue anserine (β-alanyl-N-methylhistidine) are the main HCDs in 
the skeletal muscle; in the cardiac muscle, acetylated analogues of car-
nosine (N-Acetyl-L-carnosine) and anserine (N-Acetyl-L-anserine) are 
also expressed in high amounts [2]. Carnosine is endogenously syn-
thesised by carnosine synthase 1 [3], an enzyme that is encoded by the 
CARNS1 gene. Following carnosine formation, other HCDs can be syn-
thesised via carnosine methylation (anserine and ophidine), via carno-
sine acetylation (N-Acetyl-L-carnosine) or via anserine acetylation 
(N-Acetyl-L-anserine) [4], although little is currently known about car-
nosine and anserine acetylation reactions. HCDs are among the most 
abundant metabolites in striated muscles [5]. 
Carnosine and its analogues can be obtained from the diet and their 
endogenous synthesis can be increased via β-alanine supplementation, 
with the availability of β-alanine being rate-limiting for carnosine syn-
thesis [6]. Although the physiological roles of carnosine have been 
studied for decades, a definitive conclusion remains elusive. The pKa of 
carnosine is 6.83 [7], leading to the assumption that it is a proton (H+) 
buffer in skeletal muscle [8]. This is supported by the fact that increased 
muscle carnosine content increases high- but not low-intensity exercise 
tolerance [9] and by comparative physiology data [10]. Several other 
properties ascribed to carnosine might also be physiologically relevant, 
including protection against oxidative stress [1] and protein glycation 
[11], detoxification of reactive aldehydes [12] and regulation of Ca2+
handling in striated muscles [13,14], suggesting that carnosine is 
multifunctional and pluripotent. Its exact role(s) in the different tissues 
where it is located remain unclear, especially as most of the evidence 
arises from in vitro studies. The presence of HCDs in cardiac muscle [5] 
and in some brain areas [15] suggests other possible roles that are still 
unknown. The available evidence indicates that carnosine and other 
HCDs exert diverse, although ultimately beneficial, effects on cellular 
function. For example, carnosine appears to delay cell senescence and 
rejuvenate senescent cells in vitro [16], whilst at the same time it seems 
capable of inhibiting the growth of some tumour cells [17], suggesting 
that the pluripotency of carnosine might have differential tissue-specific 
functions. 
Here, we report the development and characterisation of a novel 
CARNS1 gene knockout (CARNS1− /− ) rat strain in which all tissues are 
devoid of HCDs. This approach enabled us to explore, for the first time, 
whether the antioxidant, pH-buffering and Ca2+ handling properties of 
carnosine translate into physiologically relevant roles for normal cell 
and tissue function. An advantage of the rat model is that their normal 
HCDs content is comparable to that of humans [1], which increases the 
translational value of the study. Our data reveals that HCDs are key 
regulators of excitation-contraction (EC) coupling in cardiac, but not in 
skeletal muscle, opening a new avenue for exploring the therapeutical 
role of HCDs. 
2. Materials and methods 
2.1. Development of CARNS1− /− rats 
CARNS1− /− rats were generated by an outsourced company 
(Transposagen Inc., USA) with the use of CRISPR-Cas9 technology. Two 
CRISPR guides (5′-GGCTCAGTGGCTGGCGCTGG and 5′- 
GGGATTGCTGGAGAAGCTGG) targeting exon 6 of the CARNS1 gene 
were injected, along with Cas9 mRNA, into the pronuclei of 46 Wistar 
rat embryos, four of which were born alive. The resulting mutations 
were screened by amplicon sequencing and comprised large exonic se-
quences (>80 bp) that induced frameshift. Three pups showed signs of 
deletion, with three slightly different alleles being transmitted to the 
offspring of two founders, thereby confirming germline transmission. All 
founders were genotyped, and the three expected mutated alleles were 
confirmed. Because the mutations were similar in their gene locations 
and sizes, we examined whether they resulted in the same phenotype (i. 
e., absence of HCDs in striated muscles). Animals carrying two of the 
three mutated alleles in any combination were considered CARNS1− /− . 
2.2. Animals 
Male Wistar CARNS1− /− rats and their wild type (WT) controls were 
housed in groups of 4–5 per cage and were maintained in a controlled 
environment (temperature 23 ± 2 ◦C, relative humidity at 55 ± 10%, 
12/12 h light/dark cycle) with ad libitum access to standard laboratory 
chow (Nuvilab/Quimtia, Brazil) and filtered water up to their 4th month 
of age, when they were used for the experiments. All experiments were 
carried out with the researchers blinded to genotype and were repeated 
a minimum of 3 times using different groups of animals. The study was 
approved by the Animal Use Ethics Committee of the University of Sao 
Paulo (#2014/04) and complied with the normative resolutions (N◦. 
30–32/2016) of the Brazilian National Council for Animal Experimen-
tation Control (CONCEA). 
2.3. Genotyping 
Genomic DNA was extracted from the ear clips using the salting-out 
method and then submitted to PCR reaction (5x buffer; 25 mM MgCl2; 
10 μM dNTPmix; 10 μM Primer (forward and reverse); DNA 0,5 μL; Go 
Taq DNA Polymerase (5u/μL) and Ultrapure water). Thermal cycling 
conditions were: 2 min 95 ◦C for 2 min; 35 cycles of 95 ◦C for 30 s, then 
59 ◦C for 45 s and 72 ◦C for 1 min; 5 min 72 ◦C. PCR products were 
separated in 2% agarose gel electrophoresis and visualised in UV 
transilluminator. 
2.4. Phenotype confirmation 
To confirm that CARNS1− /− resulted in the absence of HCDs, car-
nosine and anserine were quantified in duplicate in skeletal muscle 
using HPLC coupled to UV detection [18], and in cardiac muscle using 
HPLC coupled to mass spectrometry (ESI + MS/MS) [12]. Approxi-
mately 3–4 mg of lyophilised skeletal and cardiac muscles tissues were 
powdered and deproteinised with 0.5 M HClO4, vortexed for 15 min and 
centrifuged at 5000 g at 4 ◦C for 3 min [19]. Samples were neutralised 
with 2.1 M KHCO3, centrifuged at 5000 g at 4 ◦C for 3 min, and the 
supernatant stored at − 80 ◦C for further analysis. Total skeletal muscle 
HCDs content was determined by HPLC (Lachrom, Merck Hitachi; 
Tokyo, Japan), as per Mora et al. [18]. All chromatography was con-
ducted at room temperature. Samples and standards were analysed in 
duplicate and injected via an auto sampler using a cut injection method, 
with a total aspirated volume of 70 μL; 30 μL was discarded, 10 μL was 
injected for analysis, and the remaining 30 μL was also discarded. The 
column used for chromatographic separation was an Atlantis HILIC 
silica column (4.6 × 150 mm, 3 μm; Waters, Milford, MA) attached to an 
Atlantis Silica column guard (4.6 × 20 mm, 3 μm). The method used two 
mobile phases: mobile phase A, 0.65 mM ammonium acetate, in 
water/acetonitrile (25:75) (v/v), and mobile phase B, 4.55 mM ammo-
nium acetate, in water/acetonitrile (70:30). The pH of both solutions 
was adjusted to 5.5 using ammonium hydroxide and filtered under 
vacuum through a 0.2-μm membrane. The separation condition was a 
linear gradient from 0% to 100% of solvent B in 13 min at a flow rate of 
1.4 mL/min. Separation was monitored using an ultraviolet detector at a 
wavelength of 214 nm. The column was equilibrated for 5 min under the 
initial conditions before each injection. Quantification was performed 
using peak areas, which were calculated by computer software coupled 
to the chromatographer. The peak area for the standard curve was 
plotted and a regression equation obtained, from which interpolations 
were used to calculate content. Total cardiac muscle HCDs was deter-
mined by on-line HPLC-ESI + -MS/MS was performed as described 
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before [12] with modifications. The analyses were carried out in the 
positive mode and detection was conducted on a triple quadrupole mass 
spectrometer API 6500 (Sciex, Washington D.C, WA), using selected 
reaction monitoring (SRM). An Agilent HPLC system (Agilent Technol-
ogies, Santa Clara, CA) equipped with an autosampler (1200 High per-
formance), a column oven set at 45 ◦C (1200 G1216B), an automated 
high pressure flow switching valve, a 1200 Binary Pump SL and a Shi-
madzu 10-AVp Isocratic Pump (Shimadzu, Tokyo, Japan) were used for 
sample injection and cleanup on a Kinetex C18 column, with an i.d. of 
100 × 4.6 mm and particle diameter of 2.6 μm (Phenomenex, Torrance, 
CA) followed by a second Kinetex C18 column, with an i.d. of 100 × 2.1 
mm and particle diameter 2.6 μm (Phenomenex, Torrance, CA). The 
mobile phase consisted of 5 mM ammonium acetate pH 5.5 (A) and 
acetonitrile (B). Prior to use, both solutions were filtered through a 0,22 
μm PVDF membrane (Millipore, Bedford, MA). The dipeptide was eluted 
from the columns according to the following method: from 0 to 4 min, 
10% acetonitrile and 150 μL/min; from 4 to 4.1 min flow rate was 
increased from 150 to 200 μL/min; from 4 to 6 min, 10–25,5% aceto-
nitrile and then increased to 30% acetonitrile from 6 to 10 min. From 10 
to 15 min, 30–90% acetonitrile and 200–250 μL/min; from 15 to 20 min, 
90% acetonitrile and 90-10% acetonitrile with decrease of the flow rate 
from 250 to 200 μL/min from 20 to 22 min, followed by equilibration 
step with decreasing flow rate from 200 to 150 μL/min and 10% 
acetonitrile until 32min. A high-pressure flow switching valve composed 
of 2-positions and 6-ports was inserted between the two columns. The 
valve discarded the eluent from the first column until 3 min of run while 
kept the second column supplied with a solution of ammonium acetate 5 
mM: acetonitrile (9:1, v/v) at a constant flow of 150 μL/min using a 
Shimadzu 10-AVp Isocratic Pump. After 3 min of run, the valve switched 
position allowing the eluent from the first column to enter the second 
column. Upon elution from the second column, the samples were 
injected into the mass spectrometer. After 18 min of run, the valve 
switched back to the initial position, allowing both columns to 
re-equilibrate. Carnosine and anserine were analysed by electrospray 
ionization (ESI) in the positive mode, and detection was made using 
selected reaction monitoring (SRM) on a triple quadrupole mass spec-
trometer API 6500. The Turbo Ionspray Voltage was kept at 5500 V, the 
curtain gas at 20 psi and the nebulizer and auxiliary gas at 40 psi. The 
temperature was set to 500 ◦C, and the pressure of nitrogen in the 
collision cell was adjusted to medium. The signal to noise ratio (S/N)≥ 7 
was used as the quantification criteria. Transitions for anserine: Quan-
tification transition (m/z); Confirmation transition (m/z) (241 → 170; 
241 → 109). Transitions for CAR: Quantification transition (m/z); 
Confirmation transition (m/z) (227 → 110; 227 → 156) and CARd4 (231 
→ 110; 231 → 156) were monitored using a dwell time of 50 ms. 
2.5. Body mass, fasting blood glucose and body temperature assessment 
Body mass was measured on a digital scale every 30 days, starting 
from the 30th day of life until the 110th day of life. Blood glucose was 
measured after a 6-h fast. Three measurements were taken, with an in-
terval of one week. Tail-tip blood samples were collected, and blood 
glucose was immediately determined using a blood glucose analyser 
(Accu-chek® Performa, Roche Diagnostics KK, Japan). Core body tem-
perature was measured by inserting a temperature sensor (Inconterm) in 
the animals’ rectum after anaesthesia with isoflurane (2%). 
2.6. Direct measurement of blood pressure 
Under anaesthesia, an arterial cannula was inserted into the femoral 
artery and externalised on the animal’s back. Twenty-four hours after 
surgery, arterial cannulas were connected to a pressure transducer, 
which was coupled to a signal acquisition system (PowerLab System and 
LabChart 8.0 Software, AD Instruments, Bella Vista, NSW, Australia). 
Blood Pressure (BP) was measured at a sampling frequency of 2 KHz 
(2000 samples per second) during 30 min of recording. 
2.7. Skeletal muscle morphology 
Tibial anterior and soleus muscles were cut in 10 μm cross sections 
using a cryostat (Leica CM1850, Leica Microsystems, Germany). Histo-
logical sections were subjected to hematoxylin and eosin (HE) staining. 
The images were recorded on a light microscope with 200x 
magnification. 
2.8. Exercise tolerance test 
A graded maximal running test was performed on a motorised 
treadmill. The test started at a speed of 6 m min− 1, which was increased 
by 3 m min− 1 every 3 min until exhaustion. The test was conducted at 
0% inclination and the rats were deemed exhausted when they could no 
longer maintain speed over 3 min [20]. 
2.9. In situ skeletal muscle function assessment 
Skeletal muscle contractile function was assessed in situ using a 
protocol adapted from Kalmar and Greensmith [21] and MacIntosh, 
Esau, Holash and Fletcher [22]. Animals were anesthetised with tri-
bromoethanol (20 mg kg/100 g body mass i.p.) and the sciatic nerve was 
exposed and connected to a platinum electrode. The distal tendon of the 
tibialis anterioris was connected to a surgical silk suture, which was 
connected to a previously calibrated force transducer. The sciatic nerve 
was stimulated using an S48 square pulse stimulator (Grass®) and the 
contractile data were acquired and processed using a data acquisition 
system (Biopac Systems, USA; AcqKnowledge software, version 4.4). 0.5 
V pulses were used to maximise motor unit recruitment. The stimulation 
protocol consisted of three successive steps separated by 60 s intervals: 
1) Single twitch: 5 isolated pulses at 1 Hz, 200 ms duration; 2) Maximum 
tetanic force: one pulse train at 150 Hz, duration 300 ms; 3) Fatigue test: 
one pulse train per second at 40 Hz, with the duration of 333 ms for 3 
min. 
2.10. Muscle buffering capacity (βmin vitro) 
Non-bicarbonate buffering capacity of skeletal muscle was deter-
mined using the homogenate titration method [23], completed at 37 ◦C 
in a dry bath mixer. Approximately 3 mg of freeze-dried muscle was 
homogenised on ice for 3 min in 10 mM NaF (100 μl for every 3 mg of 
dry muscle). Homogenate pH was initially adjusted to 7.1 (0.02 M 
NaOH) and then titrated to a pH of 6.5 by serial addition of 10 mM HCl, 
with the βmin vitro being calculated as the amount of H+ (in millimoles) 
necessary to change pH from 7.1 to 6.5. 
2.11. In vivo echocardiographic assessment of cardiac function 
Echocardiograms were performed with the Vevo 2100 Ultrasound 
System (Visual Sonics, Canada) under anaesthesia with 2% isoflurane. 
Sonographic structural parameters were determined using M-mode and 
two-dimensional (B-mode) images. Wall thickness and left ventricular 
chamber diameter were calculated from linear measurements, and the 
ejection fraction was calculated by the Teicholz method [24]. Tissue 
Doppler was measured in the mitral valve annulus with image of the four 
cardiac chambers to record systolic and diastolic myocardial velocities. 
2.12. In vivo electrocardiographic assessment of cardiac electrical activity 
Cardiac electrical activity was assessed under anaesthesia (2% iso-
flurane) with heart rate between 300 and 400 bpm. Electrodes were 
placed to mimic the DII lead in humans (i.e., negative and positive poles 
in the thorax at the right and left axillary region, and the ground elec-
trode on the medial face of the left pelvic limb). Cardiac electrical ac-
tivity was recorded for 10 min (Animal BioAmp/PowerLab System and 
LabChart 8.0 Software, AD Instruments, Bella Vista, NSW, Australia) 
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with a sampling rate of 2000 points per second. 
2.13. In vitro sarcomere contractile function and Ca2+ transient 
assessment 
Left ventricle cardiomyocytes were isolated as described elsewhere 
[25]. Cardiomyocytes were loaded with Fura-2/AM (1 μM, Thermo 
Fisher) for 20 min, washed and allowed to rest for a further 40 min. 
Cardiomyocytes were then stimulated at 0.5 Hz and intracellular Ca2+
concentration was measured by fluorescence counting 510 nm emissions 
after excitation at alternating wavelengths of 340 and 380 nm 
(F340/380ratio). Sarcomere shortening was recorded under the same 
stimulus by video-based sarcomere spacing acquisition system (SarcLen, 
IonOptix, Milton, MA, USA). Changes in sarcomere length were recor-
ded and analysed using the IonWizard software (IonOptix, Milton, MA, 
USA). 
2.14. Cardiac muscle morphology 
Cardiac muscles were fixed in 10% buffered formalin solution, sub-
mitted to paraffin blocking processing and cut in 5 μm cross sections, 
which were stained with hematoxylin and eosin. The images were 
recorded on a light microscope (Zeiss LSM510Meta) with 400x magni-
fication, and the micrographs were processed using Image ProPlus 6.0 
software (Media Cybernetics). 
2.15. Collagen profile area density 
Histochemical characterisation of total collagen in cardiac muscle 
was performed in 5 μm cross-sections with Sirius red staining and ana-
lysed under a polarised light optical microscope. Ten histologic fields 
per slide were used for collagen area analysis, determined by optical 
density. 
2.16. Assessment of cardiac mitochondrial function 
Cardiac mitochondria were isolated as described elsewhere [26]. To 
assess cardiac mitochondrial function, O2 consumption and hydrogen 
peroxide (H2O2) release were evaluated in isolated mitochondria [27]. 
O2 consumption was monitored using a computer-interfaced Clark-type 
electrode (OROBOROS, Oxygraph-2k) and H2O2 was measured by 
spectrofluorimetry (F-2500 Hitachi). Both experiments were performed 
in 0.25 mg of isolated cardiac mitochondria in 2 ml of experimental 
buffer (125 mM sucrose, 65 mM KCl, 10 mM Hepes, 2 mM inorganic 
phosphate, 2 mM MgCl2, 100 μM EGTA, and 0.01% BSA, pH 7.2) con-
taining succinate, malate, and glutamate substrates (2 mM of each) with 
continuous stirring at 37 ◦C. To estimate O2 consumption and H2O2 
release during State 3 and State 4 respiratory rates, and in uncoupled 
mitochondria, we added ADP (1 mM, Amresco), oligomycin (1 μg ml− 1, 
Sigma-Aldrich) and FCCP (0.1 mM). The Amplex Red (25 
μM)-horseradish peroxidase (0.5 U ml.− 1, Sigma-Aldrich) system was 
used to measure H2O2 release (λex = 563/λem = 587 nm). Calibration 
was conducted by adding H2O2 at known concentrations (A240 = 43.6 
M− 1 cm− 1) to the experimental buffer. 
2.17. Assessment of protein carbonyl in cardiac muscle 
Protein carbonylation was determined using a DNPH (2,4-dini-
trophenylhydrazine)-based colorimetric assay kit (ab126287 - Abcam) 
following manufacturer’s recommendations. 
2.18. Immunoblotting 
Tissue samples were homogenised in 30 vol of extraction buffer 
(0.625% Nonidet P-40, 0.625% sodium deoxycholate, 6.25 mM sodium 
phosphate pH 7.2, 1 mM EDTA pH 8.0, 1% phosphatase and protease 
inhibitor cocktails). Total protein was quantified in the supernatant 
using the Bradford protein assay and 20–40 μg of protein was loaded 
into polyacrylamide gel for electrophoresis. SERCA2 was separated in a 
12% gel while Phospholamban was separated in a 4–20% gradient 
precast gel (Mini-PROTEAN® TGX™, BioRad). After separation, pro-
teins were transferred to a nitrocellulose membrane using a transfer 
buffer containing 10% methanol. Membranes were then blocked with 
5% skim milk and incubated overnight with the primary antibody 
diluted in 5% BSA in the following concentrations: anti-Serca2 (ab3625, 
1:1000), anti-Phospolamban (Abcam, ab85146, 1:1000), anti-Phospo-
lamban-Phospo (ab62170, 1:1000). Membranes were then incubated 
with secondary antibodies conjugated with peroxidase (goat anti-rabbit 
polyclonal, Jackson ImmunoResearch 111–035003; 1:10000) for 1 h. 
Protein bands were visualised using ECL Western Blotting Substrate 
(32106) in a Syngene G:BOX image acquirer. 
2.19. Real-time RT-PCR 
The expression of PHT1 and PHT2 genes (encoding carnosine 
transporting proteins) was assessed in left ventricles via real-time RT- 
PCR. Total RNA was isolated using Trizol® (Invitrogen) and chloroform 
and precipitated in isopropanol. RNA concentration and purity were 
measured in a micro-spectrophotometer (NanoDrop ND2000, Thermo 
Scientific), with integrity being confirmed in denaturing agarose gel. 
cDNA was synthesised with oligo DT and M-MLV reverse transcriptase 
(Promega). PCR was carried out with 20 ng cDNA, 22 μl SYBR™ Green 
(Applied Biosystems) and 300 nM of each primer in a final volume of 44 
μl. The cycling conditions were: 50 ◦C for 2 min, 95 ◦C for 10 min, 40 
cycles of 95 ◦C for 15 s and 60◦ for 60 s, and a final 65-95 ◦C melting 
ramp with 1 ◦C increments. Signal intensity was monitored using the 
Rotor Gene-Q HRM system (Qiagen). Relative gene expression was 
calculated using the 2− ΔΔCt method with the YWHAZ gene being used as 
the reference gene. Primers sequences were as follows: PHT1 5′- 
GAGGGCCGTTCACAGAGGA-3′ and 5′-TGAGGCCTTATAGTCTGCAG-3’; 
PHT2 5′- GAGTCTGGGTCACGGAGAC-3′ and 5′- GAGGCCCACGAT-
GATGCTG-3’. 
2.20. Data analysis 
Data are presented as mean ± SD. Body mass and force production in 
the fatigue test were analysed with mixed models (proc mixed, SAS v. 
9.4). Post-hoc tests, corrected for multiple comparisons with the Tukey- 
Kraemer adjustment, were used to locate significant differences when-
ever significant main effects or interaction effects were shown. The 
distribution of total collagen area was compared between genotypes 
using the Kolmogorov-Smirnov test (RStudio v.4.0.0). For all other 
variables, Welch’s two-sample t-tests for unequal sample sizes were used 
to compare CARNS1− /− vs. WT (RStudio v.4.0.0). Effect sizes (ES) were 
calculated using Cohen’s d (Mean1 - Mean2)/SDpooled) when sample 
number between the groups was similar, and when different, the Hed-
ges’ g correction was used (1–3/4(n-9) [28]. 
3. Results 
3.1. CARNS1− /− lead to complete HCDs depletion in striated muscles 
CARNS1− /− rats were generated by Transposagen Inc. (USA) using 
the CRISPR-Cas9 technology to induce large intronic mutations (>80 
bp) resulting in frameshift (Fig. 1A–B). In our laboratory, they were 
genotyped and bred to homozygosity. CARNS1− /− genotype resulted in 
the absence of HCDs in skeletal (Fig. 1C–D) and cardiac (Fig. 1E and F) 
muscles. The complete absence of HCDs resulted in viable animals, 
demonstrating that HCDs are not essential to life. These results also 
indicate that our model is suitable to investigate the impact of an 
absence of carnosine and other HCDs on striated muscle homeostasis in 
vivo. 
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3.2. CARNS1− /− resulted in an apparently normal phenotype 
Visual inspection showed no impact of the absence of HCDs on gross 
phenotype (Fig. 2A). Likewise, histological analyses of skeletal and 
cardiac muscles showed preserved morphological characteristics 
(Fig. 2B). CARNS1− /− did not affect fertility, as assessed by the number 
of viable pups per mating (Fig. 2C), nor did it affect somatic growth 
(Fig. 2D), or body temperature (Fig. 2E). No differences in cardiac and 
skeletal muscle mass were shown between genotypes (Fig. 2F and G). 
Evidence from cultured cells suggests that carnosine might increase 
glucose uptake by skeletal muscle [29]. We thus explored whether 
glucose metabolism would be impacted by CARNS1− /− , but we showed 
no effect of an absence of HCDs on occasional glycaemia (Fig. 2H); as 
such, no further effects on glucose metabolism were examined. 
3.3. CARNS1− /− did not affect exercise capacity and muscle buffering 
capacity 
Increased intramuscular carnosine improves high-intensity exercise 
capacity, likely due to its H+ buffering effect [30] and possibly due to 
improved force-generation in response to augmented Ca2+ sensitivity 
[31]. To test whether the absence of HCDs results in impaired exercise 
tolerance, animals were submitted to a progressive maximal exercise 
test on a treadmill. Contrary to our hypothesis, exercise tolerance was 
similar between CARNS1− /− and their WT controls (Fig. 2I), suggesting 
that the absence of HCDs does not affect muscle buffering capacity or 
Fig. 1. A) Two CRISPR guides were designed targeting exon 6 of the CARNS1 gene aiming at large deletions and frameshift. They were injected along with Cas9 into 
pronuclei of rat embryos. B) Offspring were screened via gene sequencing and 3 mutated alleles were identified. The red numbers display their chromosome po-
sitions, the DNA sequences in white display their deleted sequences, along with the size of the deletions. PCR genotyping confirmed amplicon sizes (upper gel images 
were carried out at Transposagen Inc.). In-house genotyping of rats bred to homozygosity confirmed transmission of mutated alleles. C and D) Representative 
chromatograms and HCD quantification via HPLC in skeletal muscle samples of WT and CARNS1− /− rats. Signals below the limits of detection were deemed zero. E 
and F) Representative SRM chromatograms and histidine-containing dipeptide quantification via HPLC-ESI + -MS/MS in cardiac muscle samples in WT and 
CARNS1− /− rats. The signal to noise ratio of ≥3 was used as the detection criteria for the adducts and a S/N ≥ 7 was used as the quantification criteria. Values below 
this threshold were deemed zero. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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muscle function. 
We next determined the in vitro buffering capacity of skeletal muscle 
extracts, which confirmed the lack of effect of the absence of HCDs on 
muscle buffering capacity (Fig. 2J). In addition to the putative role of 
carnosine on skeletal muscle pH-regulation, it has been shown that 
carnosine induces a rapid Ca2+ release from the sarcoplasmic reticulum 
[13], and increases the sensitivity of Ca2+-channels [13] and the con-
tractile apparatus to Ca2+ [31]. Indirect evidence from human studies 
has also suggested that carnosine could potentiate Ca2+ reuptake to the 
sarcoplasmic reticulum [32]. We thus investigated whether the absence 
of HCDs affects force generation, contractile properties and tolerance to 
fatigue via in situ electrical stimulation of the sciatic nerve. 
Fig. 2. A) Representative photograph of 4-month-old CARNS1− /− and WT rats showing no apparent phenotypic difference between genotypes. B) Representative 
hematoxylin and eosin-stained histological slides of skeletal (m. soleus) and cardiac muscle depicting normal tissue morphology. C) Number of pups per mating couple 
during three generations, indicating that the absence of HCDs does not affect fertility. D) Body mass was similar between genotypes (WT: n = 28; CARNS1− /− : n =
28). Mixed models: main effect of time: F(3, 50.4) = 1276.56, p < 0.0001; main effect of genotype: F(1, 55.1) = 2.57, p = 0.11; genotype*time interaction: F(3, 50.4) 
= 0.23, p = 0.88. *p < 0.05 vs. the previous time point (within-group effects). E-H) Physiological parameters (rectal temperature: WT n = 16, CARNS1− /− n = 17; 
heart mass: WT n = 27, CARNS1− /− n = 23; m. soleus mass: WT n = 27, CARNS1− /− n = 23; occasional glycaemia: WT n = 16, CARNS1− /− n = 17) were similar 
between genotypes. I) Distance covered in a progressive maximal running test (WT: n = 4, CARNS1− /− : n = 6). J) The in vitro determined muscle buffering capacity 
(WT: n = 15, CARNS1− /− : n = 15; ES: − 0.04). 
Fig. 3. A) Individual and mean-group electrically-evoked force responses to a 3-min fatigue protocol (WT: n = 7, CARNS1− /− : n = 10). No significant differences 
were shown between genotypes. (Mixed models: main effect of time: F (7, 9) = 38.21, p < 0.0001; main effect of genotype: F(1, 15) = 0.84, p = 0.37; genotype*time 
interaction: F(7, 9) = 1.15, p = 0.41. *p < 0.05 vs. the previous time point (within-group effects). B and C) Representative electrically-evoked maximal tetanic and 
single twitch contractions showing the similarities between WT and CARNS1− /− rats. D and E) Peak force (ES: − 0.31) and time to peak (ES: − 0.24) during 
electrically-evoked maximal tetanic contraction (WT: n = 7, CARNS1− /− : n = 10). F–H) Peak force (ES: − 0.10), time to peak (ES: − 0.27) and half-relaxation (ES: 
− 0.68) time during electrically-evoked single twitch contraction (WT: n = 7, CARNS1− /− : n = 10). All p-values displayed in the dot plots refer to Welch two-sample 
t-tests. 
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3.4. CARNS1− /− did not affect skeletal muscle contractility 
The absence of HCDs did not impact muscle resistance to fatigue 
(Fig. 3A), corroborating the absence of changes in exercise tolerance, H+
buffering and muscle function. Since intramuscular acidosis can play a 
major causative role in fatigue [33], our data provide novel evidence 
that HCDs might not be essential for intramuscular pH regulation. 
Moreover, peak force attained in both single twitch and maximal tetanic 
contractions, as well as time to peak force and half-relaxation time were 
also similar between CARNS− /- and WT animals (Fig. 3B–H). Since the 
contraction-relaxation cycle in skeletal muscle is mainly dependent 
upon Ca2+ transients [34], these findings suggest that HCDs are not 
essential for Ca2+ handling, at least in the skeletal muscle under normal 
conditions. 
3.5. CARNS1− /− resulted in abnormal cardiac function 
We next assessed in vivo cardiac function using echocardiography, 
which showed evidence of impaired function (Fig. 4A). Specifically, 
CARNS1− /− rats displayed increased isovolumetric contraction time 
Fig. 4. A) Representative images of B- and M-mode in vivo echocardiographic assessment of cardiac function in CARNS1− /− rats and WT controls. B-G) Isovolumetric 
contraction time (IVCT - ES: − 1.26), systolic perfusion velocity (S’- ES: 1.01), left ventricle ejection fraction (LVEF % - ES: 1.27) and left ventricle shortening fraction 
(% LVSF – ES: 1.28) (WT: n = 8, CARNS1− /− : n = 10), end systolic volume and cardiac output adjusted by body mass (WT: n = 4, CARNS1− /− : n = 7; ES: − 1.42). H-J) 
Resting heart rate measured during electrocardiogram (WT: n = 7, CARNS1− /− : n = 7; ES: − 1.16), left ventricular systolic and diastolic diameter adjusted by body 
mass (WT: n = 4, CARNS1− /− : n = 7; ES: − 2.32 and − 1.86, respectively). K-L) Representative images of total collagen positive signal in the cardiac tissue and density 
plot of total collagen quantification in the WT (n = 5) and CARNS1− /− (n = 5) groups (Kolmogorov-Smirnov test for between-genotype differences in distributions – 
ES: − 0.03). M-N) E/e’ ratio (ES: − 1.20) and cardiac performance index (TEI - ES: − 1.06) (WT: n = 8, CARNS1− /− : n = 10); O-Q) ST-wave amplitude (ES: − 1.39), T- 
wave amplitude (ES: − 2.26) and QTc interval (ES: − 1.83), (WT: n = 7, CARNS1− /− : n = 7). All p-values displayed in the dot plots refer to Welch two-sample t-tests. 
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(IVCT, Fig. 4B), suggestive of impaired systolic function [35]. A 
near-significant reduction (p = 0.057) in peak systolic annular velocity 
(S’, Fig. 4C), as well as significant reductions in left ventricle ejection 
fraction (LVEF, Fig. 4D) and left ventricle shortening fraction (LVSF, 
Fig. 4E) were shown in the CARNS1− /− rats. These results indicate that 
the absence of HCDs leads to impaired systolic function that is translated 
into greater difficulty of the left ventricle to pump blood out, thereby 
increasing the end-systolic. 
Despite the reduced systolic function, resting cardiac output was 
preserved in the CARNS1− /− rats (Fig. 4G), indicating a compensation 
for reduced ejection volume via increased chronotropism (Fig. 4H). The 
preserved cardiac output is in agreement with the lack of changes in 
exercise tolerance during the maximal running test. CARNS1− /− rats 
exhibited a loss in compliance and elastic recoil in the left ventricle, as 
indicated by the lower ejection fraction and higher end systolic volume. 
This was confirmed by a change in geometry of the left ventricle, shown 
by an increased cavity diameter during systole and diastole (Fig. 4I and 
J). To investigate whether these changes in geometry were linked with 
increased cardiac fibrosis, we assessed total collagen in cardiac tissue, 
which showed comparable content in CARNS1− /− rats in comparison 
with WT (Fig. 4K and L). Other echocardiographic parameters are dis-
played in Supplementary Table 1. 
The in vivo assessment of cardiac function showed not only systolic 
dysfunction, but also the onset of diastolic dysfunction in the CARNS1− / 
− rats, as they showed a significant reduction in the e’ wave (supple-
mentary Table 1) and a higher E/e’ ratio (Fig. 4M), indicating abnor-
malities in left ventricle relaxation, despite apparently normal E-A 
waves ratios (E/A) (supplementary Table 1). The cardiac performance 
index (TEI index) of the CARNS1− /− rats was higher than WT (Fig. 4N), 
demonstrating that global ventricular function was impaired due to the 
overload imposed on the myocardium [36]. 
3.6. Knockout of the CARNS1 gene resulted in abnormal electrical 
activity in cardiac muscle 
Using electrocardiography, we next investigated whether systolic 
and diastolic dysfunction were linked to impaired electrical activity of 
the heart. This showed significant ST-segment elevation (Fig. 4O), sug-
gesting an abnormality in phase 2 of the action potential (plateau), 
during which Ca2+ channels are opened. This corroborates the echo-
cardiographic data showing impaired systolic function and suggests that 
the underlying mechanism could be related to impaired Ca2+ handling. 
CARNS1− /− rats exhibited higher T-wave amplitudes (Fig. 4P), indi-
cating an impairment in the repolarisation phase and a possible delay in 
Ca2+ reuptake during diastole, and longer corrected QT intervals 
(Fig. 4Q). 
3.7. Knockout of the CARNS1 gene resulted in impaired sarcomere 
contractility and Ca2+ transients in isolated adult cardiomyocytes 
We next conducted ex vivo experiments in isolated adult car-
diomyocytes to confirm the impairment of contractile function and 
further investigate the involvement of Ca2+ handling on the described 
functional changes. CARNS1− /− rats showed a significant reduction in 
sarcomere shortening (Fig. 5A–B), maximal shortening (+dL/dt, 
Fig. 5C) and re-lengthening (-dL/dt, Fig. 5D) velocities, and an increased 
time to achieve 50% of maximal shortening (Fig. 5E) and 50% of 
maximal re-lengthening (Fig. 5F). Since our in vivo and ex vivo functional 
data pointed to a possible impairment in Ca2+ handling in the CARNS1− / 
− rats, we then directly examined Ca2+ transients in isolated car-
diomyocytes. Our Ca2+ transient analyses showed that Ca2+amplitude 
was lower in CARNS1− /− rats (Fig. 5G and H), with no differences be-
tween genotypes shown for basal Ca2+ and time to reach 50% of Ca2+
peak (Fig. 5I and J). The time to reach 50% of Ca2+ decay was increased 
(Fig. 5K), indicating that Ca2+ removal rates were reduced in CARNS1− / 
− rats. These findings align with early in vitro data indicating that 
carnosine has a Ca2+ activation property (Lamont and Miller, 1992), 
probably acting as an EC coupling Ca2+ regulator in the cardiac muscle. 
To further understand whether these changes could be linked to altered 
protein expression, we assessed Ca2+ handling protein expression and 
post-translational modifications via Western Blotting, which showed no 
differences between genotypes in SERCA2, total Phospholamban, 
phosphorylated PhospholambanS16+T17 expression and the total/phos-
phorylated ratio (Fig. 5L and 5M). 
3.8. No evidence of increased oxidative stress and impaired mitochondrial 
function in the CARNS1− /− rat cardiomyocytes 
A purported function of carnosine is to serve as part of the non- 
enzymatic antioxidant defence [1]. Since increased ROS production 
and oxidative stress can lead to mitochondrial dysfunction [37], we 
assessed mitochondrial function in cardiomyocytes. Our results showed 
that O2 consumption and H2O2 release by mitochondria were not 
different between genotypes (Fig. 5N, O and P). The preserved mito-
chondrial function in the CARNS1− /− rats suggests that HCDs do not 
play a relevant antioxidant role in cardiomyocytes under physiological 
conditions. 
Carnosine can bind to carbonyl groups and prevent cross-linking 
with proteins [38], with this being a major antioxidant mechanism of 
carnosine. To further explore whether this property translates into a 
physiologically relevant function, we determined protein carbonyl 
levels in cardiac tissue. No differences between genotypes were shown 
(Fig. 5Q), suggesting that HCDs are not essential for the defence against 
protein carbonylation, as previously suggested to be the case in skeletal 
muscle [10]. These data suggest that the absence of HCDs does not result 
in increased oxidative stress in cardiac tissue, and that the cellular 
mechanisms underpinning cardiac dysfunction shown in the 
CARNS1− /− rats do not involve increased oxidative stress or impaired 
mitochondrial respiration. 
3.9. Carnosine supplementation to rescue tissue HCDs levels and function 
To test whether carnosine supplementation could rescue tissue car-
nosine levels and further explore the link between HCDs and the alter-
ations shown in the previous experiments, four 4-month old female 
CARNS1− /− rats were supplemented with carnosine (1.8% in drinking 
water) for 12 weeks – a protocol that has been shown to induce large 
increases in intramuscular carnosine [39], and four male WT controls 
without supplementation were used as a reference for normal physio-
logical carnosine levels. Carnosine was determined in the tibialis ante-
rioris using HPLC/ESI+MS/MS. Despite the long supplementation 
period, no relevant increases in muscle carnosine content were observed 
(supplemented CARNS1− /− rats: 0.08 ± 0.07 mmol kg− 1 DM, range: 
0.04–0.18 mmol kg− 1 DM; WT controls: 12.1 ± 5.1 mmol kg− 1 DM, 
range: 8.8–19.6 mmol kg− 1 DM). Since we were unable to raise tissue 
carnosine to near-physiological levels, it was not possible to conduct any 
further rescue-of-function experiments in the CARNS1− /− rat model. To 
get further insight on why carnosine supplementation did not lead to 
increments in tissue carnosine, we evaluated the expression levels of the 
genes encoding PHT1 and PHT2, two proton-coupled oligopeptide 
transporters that might transport carnosine into tissues [1] and were 
previously shown to be expressed in skeletal and cardiac muscles [40]. A 
relatively low expression of these two genes (vs. constitutively expressed 
genes) was shown in the cardiac muscle, with no significant differences 
being shown between genotypes (supplemental Fig. 1). 
4. Discussion 
Our novel approach to study the role of HCDs to normal function 
shows that HCDs are important regulators of EC coupling in cardiac 
muscle, where it enhances Ca2+ amplitude during contraction and 
speeds up Ca2+ reuptake during relaxation. Our findings show that 
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carnosine, and its methylated analogues, may have potential therapeutic 
roles, especially for cardiac function, expanding recent evidence indi-
cating that increased carnosine can protect the heart against ischemia- 
reperfusion injury [41]. 
As expected, knockout of the CARNS1 gene resulted in the complete 
absence of carnosine and anserine in striated muscles, which indicates 
that carnosine synthase is the sole route for intramuscular synthesis of 
carnosine, and that anserine synthesis can only occur if carnosine is 
available. Although not measured in this study, the acetylated analogues 
of carnosine and anserine are also thought to be lacking in our model, as 
they seem to be synthesised from carnosine [1], and thus would require 
the presence of carnosine to be formed. Absence of HCDs did not result 
in embryonic lethality or any other apparent phenotypic abnormality, 
indicating that HCDs do not seem to be essential to life, but instead have 
specialised functions relevant to normal cell function, and essential to 
cardiac cell function. 
The pKa of carnosine is 6.83 [7], making it a H+ buffer across the 
physiological pH transit range in skeletal muscle. Unexpectedly, we did 
not show any evidence to support a H+ buffering role, since CARNS1− /−
animals showed no loss of exercise capacity, muscle contractile function 
or any increase in fatigability in a highly glycolytic muscle (i.e., tibialis 
anterioris). Moreover, there was no evidence of reduced in vitro muscle 
buffering capacity in the CARNS1− /− rats. Our data does not, however, 
imply that carnosine is not a H+ buffer in skeletal muscle, but rather 
indicates that carnosine is not essential to support normal buffering 
capacity and skeletal muscle function. The contribution of carnosine to 
the total muscle buffering capacity is estimated to be ~10% [6], which 
seems to be entirely compensated for when carnosine is absent. 
Although our data indicated that skeletal muscle function is not reliant 
upon HCDs, we cannot rule out that it plays specialised roles when 
present. Increased muscle carnosine has been associated with improved 
detoxification of reactive aldehydes via adduct formation [12]. Inter-
estingly, a role for carnosine in H+ buffering and aldehyde detoxification 
was shown recently in cardiomyocytes under low intracellular pH 
following ischemia in experimental models where carnosine was 
increased above physiological levels [41]. This suggests that, although 
carnosine may not exert a specific function under normal physiological 
conditions, it may offer protection under stressful conditions that chal-
lenge cellular function and survival. 
The rather similar contractile properties between CARNS1− /− and 
WT controls points to the lack of an effect of HCDs on Ca2+ handling in 
skeletal muscle. Our data disagrees with in vitro studies showing that 
Fig. 5. A–B) Representative traces and analysis of sarcomere shortening (%r.s.l, resting sarcomere length) (ES: − 0.004) (WT: n = 43 cells from 3 rats; CARNS1− /− : 
57 cells from 3 rats). C–F) Maximal shortening velocity (þdL/Dt - ES: 0.35), maximal relengthening velocity (-dL/dT- ES: − 0.22) (WT: n = 42 cells from 3 rats; 
CARNS1− /− : 57 cells from 3 rats), time to 50% of maximal shortening (ES: − 0.002) (WT: n = 43 cells from 3 rats; CARNS1− /− : n = 56 cells from 3 rats), and time to 
50% of maximal relengthening (ES: − 0.001) (WT: n = 43 cells of 3 rats; CARNS1− /− : n = 56 cells from 3 rats). G-K) Representative traces of Ca2+ transient, 
Ca2+amplitude, Basal Ca2+, time to 50% of Ca2+ peak (WT: n = 43 cells from 3 rats; CARNS1− /− : 57 cells from 3 rats), and time to 50% of Ca2+ decay (WT: n = 43 
cells from 3 rats; CARNS1− /− : 56 cells from 3 rats). L-M) Representative immunoblottings (numbers beside blots represent molecular weight in kDa) and their 
respective GAPDH-normalised density quantification showing protein expression levels in the cardiac tissue (WT: n = 8; CARNS1− /− : n = 8); ES: SERCA2 (0.78), total 
Phospholamban (− 0.81) and PhospholambanS16+T17 (− 0.48). N–P) Mitochondrial O2 consumption, mitochondrial H2O2 release and mitochondrial H2O2/O2 ratio in 
isolated mitochondria from left ventricle (WT: n = 11; CARNS1− /− : n = 12; ES: all <0.26). Q) Carbonylated protein concentration in the cardiac muscle lysate (WT: n 
= 6; CARNS1− /− : n = 5; ES: 0.40). All p-values displayed in the dot plots refer to Welch two-sample t-tests. 
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carnosine increases sensitivity of the contractile apparatus and Ca2+
channels to calcium, which was associated with increased force re-
sponses in the presence of carnosine [13,31]. Our findings are, however, 
in alignment with in vivo whole-body studies showing no effect of 
increased carnosine on muscle function [32]. Although our data do not 
refute the Ca2+ sensitising properties of carnosine, it indeed indicates 
that this function is not relevant for skeletal muscle contraction. Inter-
estingly though, our data show that carnosine does play a fundamental 
role in the regulation of Ca2+ handling in cardiac muscle cells, with a 
profound impact upon EC coupling and cardiac function. 
The crucial role of Ca2+ in EC coupling of striated muscles is well 
established [42]. Skeletal and cardiac muscle cell contraction involves 
sarcolemma depolarisation and opening of L-type Ca2+ channels, lead-
ing ryanodine receptors (RYRs) to release Ca2+ from the sarcoplasmic 
reticulum, resulting in Ca2+ spark, cross bridge formation and sarcomere 
shortening [42]. Cell relaxation is then initiated with Ca2+ being taken 
back up by the sarcoplasmic reticulum, through the action of sarco-
plasmic/endoplasmic reticulum calcium ATPase (SERCA) pumps, and to 
the mitochondria, through the action of mitochondrial calcium uni-
porters. Ca2+ can be also extruded to the extracellular medium through 
sodium-calcium exchangers [42]. Although the mechanism underlying 
the differential impact of HCDs absence between skeletal and cardiac 
muscles remains unclear, we can speculate that it might be linked to 
differences in structure and function between the isoforms of Ca2+
handling proteins expressed in the skeletal and in cardiac muscles. 
L-type channel-mediated Ca2+ influx is not relevant for skeletal muscle 
contractility, as there is a physical interaction between L-type Ca2+ and 
RyR1 channels that is capable of opening the sarcoplasmic reticulum 
[43]. In the cardiac muscle, however, the interaction between L-type 
Ca2+ and RYR2 channels is indirect and seems to involve Ca2+ as a signal 
transmitter [44]. The reduction in Ca2+ amplitude showed in the 
CARNS1− /− rats seems to suggest that HCDs are important physiological 
regulators of the interaction between L-type Ca2+ and RYR2 channels in 
the cardiomyocyte. This is further supported by a previous in vitro study 
in skinned cardiac cells, which showed that carnosine may regulate 
RYR2 opening [45]. In addition, under low Ca2+ conditions, the sensi-
tisation of contractile proteins to Ca2+ is lower in the cardiac muscle 
than in the skeletal muscle [46], reinforcing our findings that HCDs can 
be essential to myofilament cross-bridge formation and mechanical 
force development in the cardiac muscle only. 
Our data showed a slower rate of Ca2+ removal from the cytoplasm 
in cardiomyocytes and a slower sarcomere re-lenghtening in CARNS1− / 
− rats, demonstrating that HCDs are also involved in cardiac cell 
relaxation. While these effects cannot be accounted for by altered 
SERCA2 expression or Phospholamban-mediated SERCA2 activity, one 
may speculate that HCDs interact with SERCA2 in the cardiomyocyte to 
regulate SERCA2 activity or the affinity between SERCA2 and Ca2+. In 
addition, previous studies in resting isolated cardiac myocytes showed 
that Ca2+ can be transported across the cytosol in a H+-coupled manner, 
a mechanism mediated by diffusible H+ and Ca2+ buffers, such as car-
nosine and other HCDs [47]. Acidic microdomains generate a flux of 
unprotonated HCDs bond to Ca2+, which serve as Ca2+ pumps into these 
local cytosolic pockets of increased H+; there, the HCDs buffer the 
release of Ca2+ and become protonated. Because excitation and 
contraction are activated by Ca2+, this mechanism seems to be impor-
tant for normal cardiac cell function [47] and it could account for the 
impaired contractile function shown in our HCDs-absent CARNS1− /−
rats. Future studies should investigate how HCDs affect SERCA2 or RyR2 
activity to unravel the mechanistic basis underpinning the regulatory 
role of HCDs on calcium transients in the cardiomyocyte. 
Since increased oxidative stress is linked with impaired mitochon-
drial respiration, increased peroxide production and cardiac dysfunction 
[37], we sought to confirm whether the putative antioxidant role of 
carnosine would be linked with the cardiac dysfunction shown in 
CARNS1− /− rats. In contrast to in vitro studies showing that carnosine 
can interact with reactive oxygen species and prevent damage to the 
lipid components of cell membranes [48,49], our data indicate that 
HCDs are not relevant for primary intracellular antioxidant defence, at 
least in cardiac muscle under normal resting conditions. This also sug-
gests that the only clear causal link between HCDs and reduced cardiac 
function shown herein is impaired Ca2+ handling. Whilst HCDs, and 
especially carnosine, seem to be protective under conditions of exacer-
bated oxidative stress [41], our data indicate that acting as an antioxi-
dant is not a primary physiological role of HCDs in the cardiac muscle. 
A rescue-of-function experiment could provide additional evidence 
that the functional alterations reported in the CARNS1− /− are indeed 
linked with the absence of HCDs. This led us to conduct a 3-month 
carnosine supplementation experiment to initially test whether intra-
muscular carnosine could be restored to near-physiological levels in our 
knockout model. This supplementation protocol is 3 times longer than 
that used by Everaert et al. [39], who showed a >160% increase in 
muscle carnosine content. Tissue carnosine could be increased either by 
1) the uptake of β-alanine (resulting from the breakdown of carnosine 
into its constituents, owing to the action of carnosinases present in the 
gastrointestinal tract and in plasma) into cells and the subsequent cat-
alytic action of carnosine synthase to from carnosine, or 2) the direct 
uptake of intact carnosine into cells. Once carnosine is inside the cells, it 
can be converted into its methylated or acetylated analogues. In our 
model, the first mechanism is virtually impossible to occur, because 
CARNS1− /− lack carnosine synthase; thus, the direct uptake of the intact 
dipeptide is the sole route for increased tissue carnosine in response to 
supplementation. Carnosine can be transported across cell membranes 
by proton-coupled oligopeptide transporters [50], namely PEPT1, 
PEPT2, PHT1, and PHT2. While PEPT1 and PEPT2 do not seem to be 
expressed in rodent muscle, PHT1 and PHT2 have been reported to be 
well expressed [39]. Our data also confirmed that both PHT1 and PHT2 
genes are expressed in cardiac muscle, but their expression is relatively 
low in comparison with other constitutive genes (YWHAZ and HMBS). 
Nonetheless, muscle carnosine remained virtually absent in the 
CARNS1− /− rats after supplementation. The lack of meaningful in-
creases in carnosine might be due to the low expression levels of these 
genes, or due to the fact that these transporters are unspecific and 
transport a wide variety of di- and tri-peptides and histidine [51]. In fact, 
very little is known as to whether carnosine can be transported in or out 
of the striated muscles, and our data indicates that carnosine synthesis 
via carnosine synthase is the major and most important mechanism for 
maintaining intracellular carnosine within normal levels. Owing to the 
inability of the transporters PHT1 and PHT2 to promote tissue carnosine 
accrual without the presence of a functional carnosine synthase, we 
were unable to further conduct rescue-of-function experiments, which 
we acknowledge is a limitation of our model. 
To conclude, we developed and thoroughly described a novel 
CARNS1− /− rat strain; the results show that a primary function of HCDs 
in the cardiac muscle is the regulation of Ca2+ handling and EC coupling. 
The same function, however, seems not to apply in the skeletal muscle. 
HCDs seem to fulfill very specialised functions that are tissue specific. 
Our data, if replicated in humans, indicate that carnosine, anserine and 
their acetylated analogues could be promising therapeutic targets in 
cardiac diseases, especially because simple dietary interventions, can 
produce significant and consistent increases in their tissue content. 
While emerging evidence suggests that carnosine supplementation in 
patients with chronic heart failure can improve selected health out-
comes [52], studies are still scarce, with high risk of bias [53] and lack 
proper mechanistic foundations. Advancing knowledge on the control of 
HCDs homeostasis in cardiac muscle is fundamental to develop effective 
nutritional therapies. 
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